Ping An Biomedical (PASW) Ratios
Ping An Biomedical Ratios
PASW's free cash flow for Q2 2026 was $568.03K. For the 2026 fiscal year, PASW's free cash flow was increased by $0.00 and operating cash flow was $568.03K. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.76 | 0.84 | 0.89 | 1.02 | 0.93 |
| Quick Ratio | 2.74 | 0.84 | 0.86 | 0.96 | 0.72 |
| Cash Ratio | 0.05 | 0.00 | 0.01 | 0.02 | 0.00 |
| Solvency Ratio | -0.55 | -0.01 | -0.01 | 0.10 | 0.07 |
| Operating Cash Flow Ratio | -0.28 | 0.23 | -0.07 | 0.27 | -0.41 |
| Short-Term Operating Cash Flow Coverage | -0.64 | 1.46 | -0.14 | 0.59 | -1.10 |
| Net Current Asset Value | $ 40.52M | $ -10.73M | $ -9.13M | $ 1.69M | $ -5.41M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.19 | 0.54 | 0.43 | 0.39 |
| Debt-to-Equity Ratio | 0.23 | -1.50 | -7.33 | 7.73 | -14.04 |
| Debt-to-Capital Ratio | 0.19 | 2.98 | 1.16 | 0.89 | 1.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.51 | -7.91 | -13.63 | 17.82 | -35.74 |
| Debt Service Coverage Ratio | -1.21 | -0.01 | 0.03 | 0.25 | 0.23 |
| Interest Coverage Ratio | -47.88 | -0.00 | 0.35 | 6.90 | 6.06 |
| Debt to Market Cap | 0.06 | 0.00 | 0.24 | 0.21 | 0.27 |
| Interest Debt Per Share | 23.32 | 0.00 | 2.18 | 1.81 | 2.20 |
| Net Debt to EBITDA | -0.65 | 22.57 | 19.27 | 2.96 | 3.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 2.78% | 6.18% | 5.14% | 12.35% | 14.34% |
| EBIT Margin | -42.10% | 0.03% | 2.16% | 9.77% | 9.23% |
| EBITDA Margin | -42.09% | 0.54% | 2.66% | 10.13% | 9.62% |
| Operating Profit Margin | -43.05% | -0.00% | 0.74% | 9.44% | 8.31% |
| Pretax Profit Margin | -43.00% | -0.78% | 0.05% | 8.40% | 7.86% |
| Net Profit Margin | -37.57% | -1.47% | -1.20% | 6.31% | 5.24% |
| Continuous Operations Profit Margin | -37.57% | -1.47% | -1.20% | 6.31% | 5.24% |
| Net Income Per EBT | 87.36% | 188.10% | -2384.34% | 75.08% | 66.68% |
| EBT Per EBIT | 99.89% | 33482.88% | 6.81% | 89.00% | 94.59% |
| Return on Assets (ROA) | -18.75% | -2.26% | -1.24% | 8.82% | 7.07% |
| Return on Equity (ROE) | -28.36% | 17.87% | 16.96% | 157.12% | -252.79% |
| Return on Capital Employed (ROCE) | -32.43% | 0.03% | -10.57% | 235.13% | -414.24% |
| Return on Invested Capital (ROIC) | -23.05% | -0.06% | -39.37% | 20.22% | 20.50% |
| Return on Tangible Assets | -18.75% | -2.26% | -1.24% | 8.82% | 7.07% |
| Earnings Yield | -7.87% | 0.00% | -0.56% | 4.20% | 4.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.98 | 2.16 | 1.35 | 1.70 | 2.00 |
| Payables Turnover | 3.53 | 5.46 | 8.45 | 5.57 | 11.94 |
| Inventory Turnover | 75.13 | 645.78 | 24.56 | 21.70 | 5.32 |
| Fixed Asset Turnover | 73.03 | 107.20 | 153.00 | 627.38 | 173.91 |
| Asset Turnover | 0.50 | 1.54 | 1.03 | 1.40 | 1.35 |
| Working Capital Turnover Ratio | 2.25 | -9.07 | -22.41 | -62.85 | 0.00 |
| Cash Conversion Cycle | 85.70 | 102.50 | 241.56 | 166.52 | 220.57 |
| Days of Sales Outstanding | 184.33 | 168.79 | 269.91 | 215.27 | 182.56 |
| Days of Inventory Outstanding | 4.86 | 0.57 | 14.86 | 16.82 | 68.57 |
| Days of Payables Outstanding | 103.50 | 66.85 | 43.21 | 65.56 | 30.56 |
| Operating Cycle | 189.19 | 169.35 | 284.77 | 232.08 | 251.13 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -13.91 | 0.00 | -0.30 | 1.03 | -2.28 |
| Free Cash Flow Per Share | -13.91 | 0.00 | -0.30 | 1.03 | -2.28 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 45.38 | -0.63 | 4.34 | -1162.36 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 851.05 | -1162.36 |
| Operating Cash Flow Coverage Ratio | -0.61 | 1.35 | -0.14 | 0.59 | -1.08 |
| Operating Cash Flow to Sales Ratio | -0.19 | 0.17 | -0.07 | 0.18 | -0.32 |
| Free Cash Flow Yield | -3.94% | 0.00% | -3.44% | 12.24% | -30.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.79 | 0.00 | -177.68 | 23.81 | 20.06 |
| Price-to-Sales (P/S) Ratio | 4.78 | 0.00 | 2.14 | 1.50 | 1.05 |
| Price-to-Book (P/B) Ratio | 3.61 | 0.00 | -30.14 | 37.41 | -50.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -25.38 | 0.00 | -29.03 | 8.17 | -3.33 |
| Price-to-Operating Cash Flow Ratio | -25.38 | 0.00 | -29.03 | 8.16 | -3.33 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.00 | 1.56 | -3.02 | 0.00 |
| Enterprise Value Multiple | -12.00 | 22.57 | 99.59 | 17.79 | 13.94 |
| Enterprise Value | 172.41M | 10.68M | 218.96M | 206.48M | 133.45M |
| EV to EBITDA | -12.00 | 22.57 | 99.59 | 17.79 | 13.94 |
| EV to Sales | 5.05 | 0.12 | 2.65 | 1.80 | 1.34 |
| EV to Free Cash Flow | -26.82 | 0.73 | -36.00 | 9.80 | -4.25 |
| EV to Operating Cash Flow | -26.82 | 0.73 | -36.00 | 9.79 | -4.25 |
| Tangible Book Value Per Share | 97.93 | 0.00 | -0.29 | 0.22 | -0.15 |
| Shareholders’ Equity Per Share | 97.93 | 0.00 | -0.29 | 0.22 | -0.15 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.13 | -0.88 | 24.84 | 0.25 | 0.33 |
| Revenue Per Share | 73.92 | 0.00 | 4.03 | 5.59 | 7.24 |
| Net Income Per Share | -27.77 | 0.00 | -0.05 | 0.35 | 0.38 |
| Tax Burden | 0.87 | 1.88 | -23.84 | 0.75 | 0.67 |
| Interest Burden | 1.02 | -30.27 | 0.02 | 0.86 | 0.85 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.18 | 0.05 | 0.03 | 0.02 | 0.03 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.50 | -11.39 | 6.12 | 2.92 | -6.02 |
Currency in CNY